Trial reportJournal of endocrinological investigation2018
Insulin sensitivity and secretion and adipokine profile in patients with Cushing's disease treated with pasireotide.
Trial report in Journal of endocrinological investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Temporal Associations Among Body Mass Index, Fasting Insulin, and Systemic Inflammation: A Systematic Review and Meta-analysis.JAMA network open · 2021Pooled it
- Trial
- Incretin Response to Mixed Meal Challenge in Active Cushing's Disease and after Pasireotide Therapy.International journal of molecular sciences · 2022Article
- Cushing's syndrome is associated with altered adipokine profile.Frontiers in endocrinology · 2022Article
- Glucocorticoid excess and COVID-19 disease.Reviews in endocrine & metabolic disorders · 2021Review
- Pasireotide-induced hyperglycemia in a patient with Cushing's disease: Potential use of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist for treatment.Clinical case reports · 2020Article
- Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice.American journal of physiology. Endocrinology and metabolism · 2019Article
- Pituitary-Directed Therapies for Cushing's Disease.Frontiers in endocrinology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the effect of pasireotide on β-cell and adipose function in patients with Cushing's disease (CD).
methodsClinical and hormonal parameters, insulin secretion evaluated by HOMA-β and by the area under the curve (AUC
resultsDuring 12 months of pasireotide treatment, a significant decrease in weight (p = 0.004), BMI (p = 0.008), waist circumference (p = 0.009), urinary free cortisol (p = 0.007), fasting insulinaemia (p = 0.007), HOMA-β (p = 0.015) and AUC
conclusions12 months of treatment with pasireotide in CD is associated with an impairment of insulin secretion and an improvement of adipose function without any interference in insulin sensitivity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.